

REMARKS

Applicants thank the Examiner for the interview on June 30, 2004 in which the outstanding rejections in the parent application were discussed.

With entry of the instant amendment, claims 1-9 have been cancelled and new claims 10-28 have been added.

The amendments to the claims add no new matter and are supported throughout the application as filed.

Claim 10 recites an isolated Robo-specific antibody that binds a polypeptide having at least 95% identity to SEQ ID NO:8. Claim 13 recites that the antibody binds to a polypeptide of SEQ ID NO:8. Claim 20 recites an isolated Robo-specific antibody that binds to a protein of SEQ ID NO:10. Support can be found, *e.g.*, in the last paragraph of page 12; the second full paragraph of page 13; and the last paragraph on page 27.

Claims 11 and 12 recite polyclonal and monoclonal antibodies, respectively. Support can be found, *e.g.*, at the second full paragraph of page 13; and at lines 5-6 of the first full paragraph of page 29 and the second full paragraph of page 34.

Claims 14 and 15 relate to antibodies that bind to an extracellular domain. Support can be found, *e.g.*, on page 23, lines 5-6 of the second paragraph; Table 13, page 25; and on lines 5-6 of the first full paragraph of page 29.

Claims 16 and 17 relate to subsequences of SEQ ID NO:8. Support can be found, *e.g.*, on page 25, Table 13; and in Table 3, beginning on page 9.

Claim 18 recites that the antibody modulates Robo-mediated signaling. Support can be found, *e.g.*, at lines 6-8 and line 12 of the first full paragraph on page 13.

Claim 19 recites that the antibody is labeled. Support can be found, *e.g.*, at lines 16-20 on page 14.

Claims 21 and 22 recite an antibody that binds to a fibronectin domain of SEQ ID NO:10 and an immunoglobulin domain of SEQ ID NO:10, respectively. Support can be found, *e.g.*, on page 26, Table 14.

Claim 23 recites an isolated Robo-specific antibody that binds to a protein of SEQ ID NO:2, 4, 6, or 12. Support can be found, *e.g.*, in the last paragraph of page 12; the second full paragraph of page 13; and the last paragraph on page 27.

Claim 24 recites an isolated Robo polypeptide comprising at least one immunoglobulin or fibronectin domain, wherein the polypeptide has at least 25 consecutive residues of SEQ ID NO. 8 or 10. Support can be found, *e.g.*, on page 4, lines 9-10 of the first full paragraph; and the last line of page 12 bridging to the first line of page 13.

Claim 25 relates to a fusion product where a Robo polypeptide is coupled to another protein. Support can be found, *e.g.*, on page 4, lines 11-16 of the first full paragraph.


Claim 26 relates to a polypeptide comprising particular immunogenic human Robo polypeptide sequences. Support can be found, *e.g.*, on page 9-10, Table 3.

Claim 27 relates to a method of identifying a compound that modulate Robo-mediated signaling. Support can be found, *e.g.*, in the first full paragraph of page 21.

Claim 28 relates to nucleic acids that encode Robo. Support can be found, *e.g.*, on page 19.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Jean M. Lockyer
Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
JML:jml
60779141 v1